Canvaxin Melanoma Vaccine BLA Delayed Until 2007 After Trial Fails
This article was originally published in The Pink Sheet Daily
Executive Summary
Serono/CancerVax data safety monitoring board recommends halting Phase III development of Canvaxin for Stage IV melanoma due to lack of efficacy. Pivotal program for Stage III disease continues; no safety issues were identified with either study.
You may also be interested in...
CancerVax Ends Development of Melanoma Vaccine Canvaxin
CancerVax is dropping development of its cancer vaccine Canvaxin after a data safety monitoring board concludes a Phase III trial in stage III melanoma will not show a survival benefit.
CancerVax Ends Development of Melanoma Vaccine Canvaxin
CancerVax is dropping development of its cancer vaccine Canvaxin after a data safety monitoring board concludes a Phase III trial in stage III melanoma will not show a survival benefit.
Serono Onercept Psoriasis Studies Discontinued Due To Safety Concerns
Serono is discontinuing development of its anti-tumor necrosis factor agent onercept for moderate-to-severe psoriasis based on cases of sepsis reported during Phase III trials, the company said April 6